Latest Sarepta Therapeutics Inc (SRPT) Headlines
Post# of 58
Posted On: 03/13/2014 2:53:08 AM
Latest Sarepta Therapeutics Inc (SRPT) Headlines
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sarepta Therapeutics, Inc. to Contact Brower Piven Before the March 28, 2014 Lead Plaintiff Deadline -- SRPT
GlobeNewswire - Fri Mar 07, 5:51PM CST
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (Nasdaq:SRPT) common stock during the period between July 24, 2013 through November 12, 2013, inclusive (the "Class Period").
The Nasdaq's 5 Most Hated Stocks
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 07, 5:16PM CST
I actually had to do some digging to come up with the date of April 7, 2000 as the last time the technology-heavy Nasdaq Composite closed at a higher point than it did earlier this week. The broader market has been the beneficiary of a strong...
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Why Sarepta Therapeutics Inc. Might Have a Fighting Chance
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
In November, it looked like Sarepta Therapeutics had very little chance of getting an accelerated approval for its Duchenne muscular dystrophy drug eteplirsen. The company said the Food and Drug Administration did a 180, from being open to...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT
PR Newswire - Tue Mar 04, 5:29PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (Nasdaq: SRPT) common stock between July 24, 2013 through November 12, 2013.
Sarepta Therapeutics: Tale of a Biotech Rollercoaster
Chris Ahlstrand, The Motley Fool - Motley Fool - Mon Mar 03, 12:21PM CST
Sarepta Therapeutics has been on a roller coaster ride as the opportunities and risks associated with its pipeline continue to be debated by investors. In my list of 2014 biotech predictions, I stated that I believe the stock is due for an early...
SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Sarepta Therapeutics, Inc. and Certain Officers - SRPT
PR Newswire - Fri Feb 28, 2:02PM CST
Pomerantz LLP has filed a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, and docketed under 14-cv-10225 is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Sarepta between July 24, 2013 and November 12, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Sarepta Therapeutics Q4 Loss More Than Triples on a Doubling in Expenses
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 27, 11:14AM CST
Clinical-stage RNA-based therapeutics developer Sarepta Therapeutics reported its fourth-quarter earnings results before the opening bell this morning, highlighting significantly higher expenses and a widened quarterly loss. For the quarter,...
Sarepta Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Recent Corporate Developments
Business Wire - Thu Feb 27, 6:01AM CST
--2014 Financial Guidance of $110-120 Million in Non-GAAP Operating Loss
Sarepta (SRPT) Enters Overbought Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 5:52AM CST
Sarepta (SRPT) Enters Overbought Territory
5 Hated Earnings Stocks You Should Love
at The Street - Tue Feb 25, 12:24PM CST
These heavily shorted stocks could get squeezed much higher on bullish earnings.
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
Sarepta Therapeutics to Present Company Overview at the Cowen and Company 34th Annual Healthcare Conference
Business Wire - Thu Feb 20, 3:05PM CST
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the Cowen and Company 34th Annual Healthcare Conference in Boston, MA on Tuesday, March 4, 2014 at 9:20 a.m. Eastern Time. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.
The 5 Most Hated Biotechs: Myraid, Sarepta, Questcor, Ziopharm, and MannKind
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 18, 5:30PM CST
Looking at a company's short interest should be an integral part of an investor's due diligence. A high short interest isn't necessarily a reason shun a company, but understanding why investors are shorting the stock is important. The shorts may be...
3 Biotech Stocks to Avoid: Amarin, Dendreon, and Prosensa
Leo Sun, The Motley Fool - Motley Fool - Mon Feb 17, 2:37PM CST
In the stock market, everyone loves a great turnaround story. In the biotech sector, where companies can rally or plunge by the double-digits on an FDA approval or rejection, bottom-fishing investors love to search for broken stocks with overlooked...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- SRPT
GlobeNewswire - Fri Feb 14, 4:11PM CST
Pomerantz LLP has filed a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (Nasdaq:SRPT) and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, and docketed under 14-cv-10225 is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Sarepta between July 24, 2013 and November 12, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2013 Financial Results and Corporate Update on February 27, 2014
Business Wire - Thu Feb 13, 7:30AM CST
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report fourth quarter and full-year 2013 financial results before the NASDAQ Global Market opens on Thursday, February 27, 2014. Subsequently, at 8:00 a.m., Eastern Time, Chris Garabedian, Sarepta's president and chief executive officer, and Sandy Mahatme, Sarepta's chief financial officer, will host a conference call to discuss fourth quarter and full-year financial results and to provide a corporate update.
Biotech Stock Roundup: Gilead's Sovaldi Impresses, EU Nod for Biogen's Tecfidera - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 12, 7:27AM CST
Last week saw companies like Gilead coming out with strong results. There were also a few regulatory updates.
Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate
Business Wire - Mon Feb 10, 7:30AM CST
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced positive safety results from a Phase I multiple ascending dose study of AVI-7288 in healthy volunteers. AVI-7288, which uses Sarepta's advanced and proprietary PMOplus(TM) chemistry, is the company's lead drug candidate for the treatment of Marburg virus infection. Sarepta has been developing AVI-7288 under a Department of Defense contract managed by the Medical Countermeasure Systems BioDefense Therapeutics (MCS-BDTX) Joint Product Management Office.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sarepta Therapeutics, Inc. to Contact Brower Piven Before the March 28, 2014 Lead Plaintiff Deadline -- SRPT
GlobeNewswire - Fri Mar 07, 5:51PM CST
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (Nasdaq:SRPT) common stock during the period between July 24, 2013 through November 12, 2013, inclusive (the "Class Period").
The Nasdaq's 5 Most Hated Stocks
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 07, 5:16PM CST
I actually had to do some digging to come up with the date of April 7, 2000 as the last time the technology-heavy Nasdaq Composite closed at a higher point than it did earlier this week. The broader market has been the beneficiary of a strong...
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Why Sarepta Therapeutics Inc. Might Have a Fighting Chance
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
In November, it looked like Sarepta Therapeutics had very little chance of getting an accelerated approval for its Duchenne muscular dystrophy drug eteplirsen. The company said the Food and Drug Administration did a 180, from being open to...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT
PR Newswire - Tue Mar 04, 5:29PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (Nasdaq: SRPT) common stock between July 24, 2013 through November 12, 2013.
Sarepta Therapeutics: Tale of a Biotech Rollercoaster
Chris Ahlstrand, The Motley Fool - Motley Fool - Mon Mar 03, 12:21PM CST
Sarepta Therapeutics has been on a roller coaster ride as the opportunities and risks associated with its pipeline continue to be debated by investors. In my list of 2014 biotech predictions, I stated that I believe the stock is due for an early...
SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Sarepta Therapeutics, Inc. and Certain Officers - SRPT
PR Newswire - Fri Feb 28, 2:02PM CST
Pomerantz LLP has filed a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, and docketed under 14-cv-10225 is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Sarepta between July 24, 2013 and November 12, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Sarepta Therapeutics Q4 Loss More Than Triples on a Doubling in Expenses
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 27, 11:14AM CST
Clinical-stage RNA-based therapeutics developer Sarepta Therapeutics reported its fourth-quarter earnings results before the opening bell this morning, highlighting significantly higher expenses and a widened quarterly loss. For the quarter,...
Sarepta Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Recent Corporate Developments
Business Wire - Thu Feb 27, 6:01AM CST
--2014 Financial Guidance of $110-120 Million in Non-GAAP Operating Loss
Sarepta (SRPT) Enters Overbought Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 5:52AM CST
Sarepta (SRPT) Enters Overbought Territory
5 Hated Earnings Stocks You Should Love
at The Street - Tue Feb 25, 12:24PM CST
These heavily shorted stocks could get squeezed much higher on bullish earnings.
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
Sarepta Therapeutics to Present Company Overview at the Cowen and Company 34th Annual Healthcare Conference
Business Wire - Thu Feb 20, 3:05PM CST
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the Cowen and Company 34th Annual Healthcare Conference in Boston, MA on Tuesday, March 4, 2014 at 9:20 a.m. Eastern Time. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.
The 5 Most Hated Biotechs: Myraid, Sarepta, Questcor, Ziopharm, and MannKind
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 18, 5:30PM CST
Looking at a company's short interest should be an integral part of an investor's due diligence. A high short interest isn't necessarily a reason shun a company, but understanding why investors are shorting the stock is important. The shorts may be...
3 Biotech Stocks to Avoid: Amarin, Dendreon, and Prosensa
Leo Sun, The Motley Fool - Motley Fool - Mon Feb 17, 2:37PM CST
In the stock market, everyone loves a great turnaround story. In the biotech sector, where companies can rally or plunge by the double-digits on an FDA approval or rejection, bottom-fishing investors love to search for broken stocks with overlooked...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- SRPT
GlobeNewswire - Fri Feb 14, 4:11PM CST
Pomerantz LLP has filed a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (Nasdaq:SRPT) and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, and docketed under 14-cv-10225 is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Sarepta between July 24, 2013 and November 12, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2013 Financial Results and Corporate Update on February 27, 2014
Business Wire - Thu Feb 13, 7:30AM CST
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report fourth quarter and full-year 2013 financial results before the NASDAQ Global Market opens on Thursday, February 27, 2014. Subsequently, at 8:00 a.m., Eastern Time, Chris Garabedian, Sarepta's president and chief executive officer, and Sandy Mahatme, Sarepta's chief financial officer, will host a conference call to discuss fourth quarter and full-year financial results and to provide a corporate update.
Biotech Stock Roundup: Gilead's Sovaldi Impresses, EU Nod for Biogen's Tecfidera - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 12, 7:27AM CST
Last week saw companies like Gilead coming out with strong results. There were also a few regulatory updates.
Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate
Business Wire - Mon Feb 10, 7:30AM CST
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced positive safety results from a Phase I multiple ascending dose study of AVI-7288 in healthy volunteers. AVI-7288, which uses Sarepta's advanced and proprietary PMOplus(TM) chemistry, is the company's lead drug candidate for the treatment of Marburg virus infection. Sarepta has been developing AVI-7288 under a Department of Defense contract managed by the Medical Countermeasure Systems BioDefense Therapeutics (MCS-BDTX) Joint Product Management Office.
(0)
(0)Sarepta Therapeutics Inc. (SRPT) Stock Research Links
Scroll down for more posts ▼